Corvidia Therapeutics’ $60 Million Series B Financing Round

Goodwin advised Corvidia Therapeutics on the deal

Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, closed a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.

Corvidia Therapeutics is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. Presently, the Company is scientifically-focused on cardiovascular indications utilizing the study of genetic variations to ultimately deliver precise treatments to specific patients who have an unmet medical need. The Series B funding will be used to progress the lead clinical programs in chronic kidney disease and beyond as well as advance pre-clinical programs. The Company will add new talent to support these advancing programs.

The Goodwin team was led by partners Caitlin Murray (Picture) and Kingsley Taft and included associates Yasin Akbari, Noelle Dubiansky and Thomas Murphy.

Involved fees earner: Caitlin Murray – Goodwin Procter; Kingsley Taft – Goodwin Procter; Yasin Akbari – Goodwin Procter; Thomas Murphy – Goodwin Procter; Noelle Dubiansky – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Corvidia Therapeutics;


Author: Ambrogio Visconti